首页> 美国卫生研究院文献>Neuro-Oncology >P08.24PREDICTIVE FACTORS OF PERITUMORAL EDEMA IN BRAIN METASTASES
【2h】

P08.24PREDICTIVE FACTORS OF PERITUMORAL EDEMA IN BRAIN METASTASES

机译:P08.24脑转移瘤周水肿的预测因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECT: To investigate peritumoral edema and its prognostic factors in brain metastases of lung and breast cancers, and more specifically to evaluate the effect of treatment with angiotensine-II (Ang2) inhibitors. This treatment was shown in a recent study to display a significant effect in primary brain tumor edema. MATERIALS AND METHODS: We retrospectively reviewed the medical files of all patients with newly diagnosed brain metastases consulting in our institution in the years 2012 and 2013. We measured the maximal diameter of lesions DL (contrast enhancement) and peritumoral edema DE (diameter of edema minus contrast enhancement) on the first diagnostic imaging of brain metastasis. Patients under steroids or files with insufficient informations were excluded from analysis. RESULTS: A total of 157 medical files were reviewed from which 54 patients with 170 metastases were selected for analysis. There were 87 metastases of lung adenocarcinomas, 35 of small cell carcinomas, 18 of epidermoiïd lung cancer, 7 of undifferentiated and 23 of breast cancer. Median DL was 9.35mm (1-74.3), median DE was 5,98mm (0-69,5). There was no significant difference in DL or DE between the histology groups. Younger age (<65 years old), female gender and treatment with Ang2 inhibitors seem to be associated with statistically less peritumoral edema (p = 0,005; p = 0,022; p = 0,005, respectively). This finding was persistent even when the 23 metastases of breast cancer were taken out from the analysis. Both DL and DE were smaller in the 25 patients under treatment with Ang2 inhibitors (n = 84 metastases) than in the 29 patients without such treatment (n = 86 metastases) (mean DL: 10.2 vs 13.4 mm, p= 0.036; mean DE 9.5 vs 15.9 mm, p= 0.005, respectively) The delay between the diagnosis of the primary tumors and brain metastases did not have any impact on the peritumoral edema. Moreover, the diameter of edema did not seem to be associated with the location, the size or the number of lesions, neither with the pattern of contrast enhancement (annular, homogenic or necrotic). Different patterns of contrast enhancement and sizes of edema were observed even within the same patient with multiple metastases. From the main 157 files reviewed, multiple metastases were more frequent in breast cancer patients (9 patients out of 10) compared to lung adenocarcinomas (29/81) and other lung cancers (13/25). CONCLUSION: In this series of patients with lung and breast cancer, younger age (<65 years old), female gender and treatment with Ang2 inhibitors seem to be associated with statistically smaller brain metastases and peritumoral edema Peritumoral edema did not seem to be associated with any other factors like histology, delayed brain metastasis diagnosis, size, location, number of lesions or contrast enhancing pattern.
机译:目的:研究肺癌和乳腺癌的脑转移瘤周围水肿及其预后因素,更具体地说,评估血管紧张素-II(Ang2)抑制剂的治疗效果。最近的一项研究表明,这种治疗方法对原发性脑肿瘤水肿具有显著作用。材料与方法:我们回顾性回顾了2012年和2013年在我们机构咨询的所有新诊断为脑转移的患者的医疗档案。我们测量了病变的最大直径DL(对比度增强)和肿瘤周围水肿DE(水肿减直径)。对比增强)对脑转移的首次诊断成像。分析中排除类固醇激素或文件不足的患者。结果:共审查了157个医学档案,从其中选择的54例具有170个转移灶的患者进行了分析。肺腺癌有87个转移灶,小细胞癌35个,表皮肺癌18个,未分化癌7个,乳腺癌23个。 DL中位数为9.35mm(1-74.3),DE中位数为5,98mm(0-69,5)。组织学组之间的DL或DE没有显着差异。年龄较小(<65岁),女性和使用Ang2抑制剂治疗似乎与统计学上较少的肿瘤周围水肿相关(分别为p = 0,005; p = 0,022; p = 0,005)。即使从分析中排除了23种乳腺癌转移,这一发现仍然是持久的。接受Ang2抑制剂治疗的25例患者(n = 84转移)的D​​L和DE均小于未接受Ang2抑制剂治疗的29例患者(n = 86转移)(平均DL:10.2 vs 13.4 mm,p = 0.036;平均DE分别为9.5和15.9 mm,p = 0.005)诊断原发肿瘤和脑转移瘤之间的延迟对肿瘤周围水肿没有任何影响。此外,水肿的直径似乎与病变的部位,大小或数量无关,与造影剂的增强模式(环状,同质或坏死)无关。即使在具有多个转移的同一患者中,也观察到不同的对比增强模式和水肿大小。在所审查的157个主要文件中,与肺腺癌(29/81)和其他肺癌(13/25)相比,乳腺癌患者(10名患者中有9名患者)发生多处转移的频率更高。结论:在这一系列肺癌和乳腺癌患者中,年龄较小(<65岁),女性和使用Ang2抑制剂治疗似乎与统计上较小的脑转移瘤和肿瘤周围水肿有关,腹膜周围水肿似乎与任何其他因素,例如组织学,脑转移瘤诊断延迟,大小,位置,病变数量或对比度增强模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号